Takeda Pharmaceutical Company reports Phase 2/3 TAK-881 data showing PK comparability to HYQVIA in PID, with similar efficacy and potential for reduced infusion burden.
Written By: Chikkula Pavan Kumar, PharmD
Reviewed By: Pharmacally Editorial Team
Takeda Pharmaceutical Company announced that its pivotal Phase 2/3 trial (TAK-881-3001; NCT05755035) met the primary endpoint, demonstrating pharmacokinetic comparability between investigational TAK-881 and HYQVIA in patients with Primary Immunodeficiency Disease (PID).
The study showed equivalent immunoglobulin G (IgG) exposure, with a geometric mean ratio of 99.67% (90% CI: 95.10% to 104.46%), along with comparable efficacy, safety, and tolerability profiles. TAK-881 maintained protective IgG levels and showed infection rates similar to HYQVIA, with no new safety signals observed.
As a 20% subcutaneous immunoglobulin (SCIG) facilitated by recombinant human hyaluronidase, TAK-881 delivers the required dose in approximately half the infusion volume compared to HYQVIA, potentially reducing infusion time and injection sites while enabling flexible dosing every three to four weeks.
Kristina Allikmets, MD, PhD, Senior Vice President and Head of Plasma Derived Therapies R&D at Takeda, stated that TAK-881 demonstrated pharmacokinetic comparability to HYQVIA while offering advantages such as fewer injection sites, flexible dosing, and shorter infusion times. She added that the results support Takeda’s strategy to advance next-generation immunoglobulin therapies and expand patient options while maintaining established efficacy and safety standards.
Principal investigator Richard L. Wasserman, MD, PhD, highlighted that patients with PID face a significant lifelong treatment burden from regular immunoglobulin therapy. He noted the TAK-881 data are encouraging, indicating a more concentrated, hyaluronidase-facilitated subcutaneous formulation could maintain immune protection while improving the treatment experience.
The trial evaluated pharmacokinetics, efficacy, safety, tolerability, and immunogenicity in adults and pediatric patients aged 2 years and older, including randomized crossover comparison with HYQVIA in patients aged 16+ and a single-arm cohort in younger patients. A Phase 3 extension study (TAK-881-3002) assesses long-term safety; Takeda expects regulatory submissions in the US, EU, and Japan in fiscal year 2026.
Primary Immunodeficiency Disease comprises over 550 rare genetic disorders impairing immune function, often leading to recurrent infections.
Reference
About the Writer
Chikkula Pavan Kumar, PharmD is a Doctor of Pharmacy with a keen interest in clinical pharmacy, pharmacovigilance, and evidence-based practice. In his words, he is passionate about patient safety and translating complex medical information into clear, research-driven communication.